Back to Search Start Over

The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation.

Authors :
O'Brien, Emily C
O'Brien, Emily C
Simon, DaJuanicia N
Thomas, Laine E
Hylek, Elaine M
Gersh, Bernard J
Ansell, Jack E
Kowey, Peter R
Mahaffey, Kenneth W
Chang, Paul
Fonarow, Gregg C
Pencina, Michael J
Piccini, Jonathan P
Peterson, Eric D
O'Brien, Emily C
O'Brien, Emily C
Simon, DaJuanicia N
Thomas, Laine E
Hylek, Elaine M
Gersh, Bernard J
Ansell, Jack E
Kowey, Peter R
Mahaffey, Kenneth W
Chang, Paul
Fonarow, Gregg C
Pencina, Michael J
Piccini, Jonathan P
Peterson, Eric D
Source :
European heart journal; vol 36, iss 46, 3258-3264; 0195-668X
Publication Year :
2015

Abstract

BackgroundTherapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations.ObjectivesWe sought to develop and validate a novel bleeding risk score using routinely available clinical information to predict major bleeding in a large, community-based AF population.MethodsWe analysed data from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), a prospective registry that enrolled incident and prevalent AF patients at 176 US sites. Using Cox proportional hazards regression, we identified factors independently associated with major bleeding among patients taking oral anticoagulation (OAC) over a median follow-up of 2 years (interquartile range = 1.6-2.5). We also created a numerical bedside risk score that included the five most predictive risk factors weighted according to their strength of association with major bleeding. The predictive performance of the full model, the simple five-item score, and two existing risk scores (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol concomitantly, HAS-BLED, and anticoagulation and risk factors in atrial fibrillation, ATRIA) were then assessed in both the ORBIT-AF cohort and a separate clinical trial population, Rivaroxaban Once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET-AF).ResultsAmong 7411 ORBIT-AF patients taking OAC, the rate of major bleeding was 4.0/100 person-years. The full continuous model (12 variables) and five-factor ORBIT risk score (older age [75+ years], reduced haemoglobin/haematocrit/history of anaemia, bleeding history, insufficient kidney function, and treatment with antiplatelet) both had good ability to identify those who bled vs. not (C-index 0.69 and 0.67, respectively). These scores both had similar discri

Details

Database :
OAIster
Journal :
European heart journal; vol 36, iss 46, 3258-3264; 0195-668X
Notes :
application/pdf, European heart journal vol 36, iss 46, 3258-3264 0195-668X
Publication Type :
Electronic Resource
Accession number :
edsoai.on1367521036
Document Type :
Electronic Resource